BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torricelli AK, Ugolini-Lopes MR, Bonfá E, Andrade D. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus 2020;29:256-62. [PMID: 31986962 DOI: 10.1177/0961203320901598] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Weiner JK, Smith T, Hoy CK, Sarosh C, Madison JA, Ambati A, Tambralli A, Peters N, Packel C, Gockman K, Zuo Y, Briceño EM, Nagaraja V, Knight JS. Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study. ACR Open Rheumatology 2022. [DOI: 10.1002/acr2.11512] [Reference Citation Analysis]
2 Xie W, Ji L, Zhang Z. Sirolimus Monotherapy for Thrombocytopenia in Primary Antiphospholipid Syndrome: A Pilot Study From a Tertiary Referral Center. Front Immunol 2022;13:857424. [PMID: 35401500 DOI: 10.3389/fimmu.2022.857424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Madison JA, Gockman K, Hoy C, Tambralli A, Zuo Y, Knight JS. Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series. Pediatr Rheumatol Online J 2022;20:17. [PMID: 35197077 DOI: 10.1186/s12969-022-00677-8] [Reference Citation Analysis]
4 Uludağ Ö, Çene E, Gurel E, Çetin Ç, Bektaş M, Yalçınkaya Y, Diz-Küçükkaya R, Gül A, Inanç M, Artim-Esen B. Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus 2022;:9612033221079781. [PMID: 35166607 DOI: 10.1177/09612033221079781] [Reference Citation Analysis]
5 Islabão AG, Trindade VC, da Mota LMH, Andrade DCO, Silva CA. Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatr Drugs 2021. [PMID: 34904182 DOI: 10.1007/s40272-021-00484-w] [Reference Citation Analysis]
6 Radin M, Foddai SG, Cecchi I, Roccatello D, Sciascia S. Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). Eur J Intern Med 2021:S0953-6205(21)00246-6. [PMID: 34330618 DOI: 10.1016/j.ejim.2021.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chen HH, Lin CH, Chao WC. Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study. Front Med (Lausanne) 2021;8:654791. [PMID: 34041252 DOI: 10.3389/fmed.2021.654791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Erkan D, Sciascia S, Bertolaccini ML, Cohen H; APS ACTION Executive Committee. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Curr Rheumatol Rep 2021;23:45. [PMID: 33932165 DOI: 10.1007/s11926-021-01008-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Medina G, Cimé Aké EA, Vera-Lastra O, Saavedra MÁ, Cruz-Domínguez MDP, Amigo MC, Jara LJ. Damage index for antiphospholipid syndrome during long term follow-up: Correlation between organ damage accrual and quality of life. Lupus 2021;30:96-102. [PMID: 33176566 DOI: 10.1177/0961203320970651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]